Medical Advocates
Lopinavir/Ritonavir (Kaletra/Aluvia)
 
Journal Citations: Adolescent/Adult
Combination Therapies

LPV/RTV/3rd PI               LPV/RTV/Misc. Combinations
LPV/RTV/ATZ
 LPV/RTV/EFV
LPV/RTV/EFV/2NRTIs
LPV/RTV/Fosamprenavir
LPV/RTV/IND
LPV/RTV/NVP
LPV/RTV/NVP/2NRTIs
LPV/RTV/D4T/3TC
LPV/RTV/SQV
LPV/RTV/2 NRTIs
LPN/r Adult/Adol Journal Main Page LPN/r Journal Main Page Home
Last Update: July 27, 2008
 Documents identified with this icon are in Portable Document Format (PDF) and require the Adobe Acrobat Reader
LPV/RTV/3rd PI
 
  A WEEK-IN-REVIEW FEATURED REPORT
 Efficacy and Treatment-Limiting Toxicity With the Concurrent Use of Lopinavir/
Ritonavir and a Third Protease Inhibitor in Treatment-Experienced HIV-Infected
Patients.
Casau NC, Glesby MJ, Paul S, Gulick RM.
J Acquir Immune Defic Syndr 2003 Apr 15;32(5):494-8
 Abstract		  
LPV/RTV/ATZ
 
  A WEEK-IN-REVIEW FEATURED REPORT
 Atazanavir and lopinavir with ritonavir alone or in combination: analysis of pharmacokinetic
interaction and predictors of drug exposure.
Di Giambenedetto S, De Luca A, Villani P, et al
HIV Med. 2008 Apr;9(4):239-45.
 Abstract
LPV/RTV/EFV
 
  A WEEK-IN-REVIEW FEATURED REPORT
 Efficacy and Tolerability of a Nucleoside Reverse Transcriptase Inhibitor-Sparing
Combination of Lopinavir/Ritonavir and Efavirenz in HIV-1-Infected Patients.
Allavena C, Ferre V, Brunet-Francois C, et al
J Acquir Immune Defic Syndr. 2005 Jul 1;39(3):300-306.
Abstract
LPV/RTV/EFV/2NRTIs
 
 
A WEEK-IN-REVIEW FEATURED REPORT
Efficacy and safety of an anti-retroviral combination regimen including either
efavirenz or lopinavir-ritonavir with a backbone of two nucleoside reverse
transcriptase inhibitors.
Panagopoulos P, Tsiodras S, Antoniadou A, et al 
Clin Microbiol Infect. 2006 May;12(5):486-9.
 Abstract

Pharmacokinetic-pharmacodynamic analysis of lopinavir-ritonavir in combination
with efavirenz and two nucleoside reverse transcriptase inhibitors in extensively
pretreated human immunodeficiency virus-infected patients
Hsu A, Isaacson J, Brun S, et al.
Antimicrob Agents Chemother 2003 Jan;47(1):350-9
 Abstract 

 
LPV/RTV/Fosamprenavir
 
  Combining fosamprenavir with lopinavir/ritonavir substantially reduces amprenavir
and lopinavir exposure: ACTG protocol A5143 results.
Kashuba AD, Tierney C, Downey GF,
AIDS. 2005 Jan 28;19(2):145-152.
 Abstract
LPV/RTV/IND
 
  Lopinavir/ritonavir combined with twice-daily 400 mg indinavir: pharmacokinetics and
pharmacodynamics in blood, CSF and semen.
Isaac A, Taylor S, Cane P 
Antimicrob Chemother. 2004 Aug;54(2):498-502.
 Abstract
LPV/RTV/NVP
 
  Lopinavir/Ritonavir Plus Nevirapine as a Nucleoside-Sparing Approach in Antiretroviral-
Experienced Patients (NEKA Study).
 Negredo E, Molto J, Burger D, et al 
J Acquir Immune Defic Syndr. 2005 Jan 1;38(1):47-52.
 Abstract
LPV/RTV/NVP/2NRTIs
 
  Safety and Antiviral Activity at 48 Weeks of Lopinavir/Ritonavir plus Nevirapine
and 2 Nucleoside Reverse-Transcriptase Inhibitors in Human Immunodeficiency
Virus Type 1--Infected Protease Inhibitor--Experienced Patients.
Benson CA, Deeks SG, Brun SC, et al.
J Infect Dis 2002 Mar 1;185(5):599-607
 Abstract 
LPV/RTV/D4T/3TC
 
 
A WEEK-IN-REVIEW FEATURED REPORT
Seven-Year Efficacy of a Lopinavir/Ritonavir-Based Regimen in Antiretroviral-Naïve
HIV-1-Infected Patients.
Murphy RL, da Silva BA, Hicks CB, et al 
HIV Clin Trials. 2008 Jan-Feb;9(1):1-10
 Abstract

Long-term safety and durable antiretroviral activity of lopinavir/ritonavir in
treatment-naive patients: 4 year follow-up study
Hicks C, King MS, Gulick RM et al.
AIDS. 2004 Apr 12;18(5):775-779.
Abstract

FULL-TEXT ARTICLE
 ABT-378/ritonavir plus stavudine and lamivudine for the treatment of antiretroviral-
naive adults with HIV-1 infection: 48-week results.
Murphy RL, Brun S, Hicks C, et al.
AIDS 2001 Jan 5;15(1):F1-9
Paper  
LPV/RTV/SQV
 
 
A WEEK IN REVIEW FEATURED REPORT
 Pharmacokinetics of High-Dose Lopinavir/Ritonavir with and without Saquinavir or Non-Nucleoside
Reverse Transcriptase Inhibitors in HIV Infected Pediatric and Adolescent Patients Previously Treated
with Protease Inhibitors - Study PACTG P1038.
 Robbins BL, Capparelli EV, Chadwick EG, et al 
Antimicrob Agents Chemother. 2008 Jul 14.
 Abstract
 
A WEEK-IN-REVIEW FEATURED REPORT
 The LOPSAQ study: 48 week analysis of a boosted double protease inhibitor regimen
containing lopinavir/ritonavir plus saquinavir without additional antiretroviral therapy.
Staszewski S, Babacan E, Stephan C, et al 
J Antimicrob Chemother. 2006 Sep 6
 Abstract

FULL-TEXT ARTICLE
Lopinavir/ritonavir plus saquinavir in salvage therapy; pharmacokinetics,
tolerability and efficacy
la Porte C JL,  Wasmuth J-C,  Schneider K,  et al
AIDS. 17(11):1700-1702, July 25, 2003.
Letter
LPV/RTV/2 NRTIs
 
  A WEEK-IN-REVIEW FEATURED REPORT
 Efficacy and safety of an anti-retroviral combination regimen including either
efavirenz or lopinavir-ritonavir with a backbone of two nucleoside reverse
transcriptase inhibitors.
Panagopoulos P, Tsiodras S, Antoniadou A, et al
Clin Microbiol Infect. 2006 May;12(5):486-9.
 Abstract
LPV/RTV/Misc. Combinations
 
 
A WEEK-IN-REVIEW FEATURED REPORT
 High-Dose Lopinavir/Ritonavir in Highly Treatment-Experienced HIV-1 Patients:
Efficacy, Safety, and Predictors of Response.
Podzamczer D, King MS, Klein CE, et al
 HIV Clin Trials. 2007 Jul-Aug;8(4):193-204.
 Abstract

Treatment outcomes amongst previously antiretroviral-naive HIV-infected patients
starting lopinavir/ritonavir-containing antiretroviral regimens at the Royal Free
Hospital.
Smith C, Phillips A, Youle M, et al
 HIV Med. 2007 Jan;8(1):55-63.
 Abstract
 

 
LPN/r Adult/Adol Journal Main Page LPN/r Journal Main Page Home

Lopinavir/Ritonavir
Journal Papers/Abstracts/Commentaries:
Adolescent/Adult Combination Therapies